DIS ® Platform

Our Drug Intelligence Science (DIS®) platform combines cutting edge single cell technology with AI/ML analysis to enhance success from target to patient.

The DIS® Difference

Our DIS® driven approach generates profound insights into disease biology to advance groundbreaking immunomodulatory therapies. We apply DIS® across all stages of drug discovery and development to achieve higher success rates with shorter timelines.

Clinical

Comprehensive data from imaging, sequencing, PK/PD analysis, and patient history is collected and analyzed to generate data-driven predictive biomarker hypotheses. This analysis generates insights for identifying predictive biomarkers to prospectively select patients for enhanced clinical response.

Preclinical

Extensive ex-vivo and computational analysis of patient samples is performed to gain insights into disease biology for guiding indication selection and enabling more effective and efficient clinical trials.

Discovery

Target Discovery: Experimental and computational analysis of patient samples and data is used to identify relevant targets involved in diseases with high medical need. DIS® provides a cellular level high-resolution view for the identification of targets associated exclusively with disease.

Antibody Discovery: Our DIS® driven antibody discovery platform allows for the screening of millions of species agnostic B cells within hours (CelliGo™) and is powered by bioinformatics software (AbSolution™) for data analysis of single B cells. Our machine learning model guides antibody binding prediction and affinity maturation to enhance our level of efficiency with better outcomes. As a result, we have built an industry leading antibody discovery platform with an exceptional success rate and reduced timelines.

Publications

American Association for Cancer Research | Poster | Apr 09, 2024
Integrating Public Single-Cell Transcriptomics and Patient Profiles to Guide Clinical Development

Drug Discovery Today | Publication | Oct 17, 2023
Drug Intelligence Science (DIS®): Pioneering a High-Resolution Translational Platform to Enhance the Probability of Success for Drug Discovery and Development

American Association for Cancer Research | Poster | Apr 08, 2022
Discovery of Predictive Biomarkers of Response to T Cell-Targeting Biologics Using Ex Vivo Single-Cell Profiling Coupled with TCR Clonotype Characterization

Science Advances | Publication | Jun 11, 2021
High-Throughput Functional Screening for Next-Generation Cancer Immunotherapy Using Droplet-Based Microfluidics

American Association for Cancer Research | Presentation | Sep 17, 2020
HiFiBiO Therapeutics Presents Novel Approach to Patient Stratification Demonstrating DIS™ Single-Cell Platform at 2020 AACR Tumor Heterogeneity Conference

Nature Biotechnology | Publication | Mar 20, 2020
High-Throughput Single-Cell Activity-Based Screening and Sequencing of Antibodies Using Droplet Microfluidics

Nature Genetics | Publication | May 31, 2019
High-Throughput Single-Cell ChIP-Seq Identifies Heterogeneity of Chromatin States in Breast Cancer

Nature Biotechnology | Publication | Sep 11, 2017
Single-Cell Deep Phenotyping of IgG-Secreting Cells for High-Resolution Immune Monitoring

HiFiBio, Paris | Poster | Nov 13, 2016
Antibody Discovery by Deep Mining of Immune Repertoires: A Demonstration of the HiFiBiO CelliGO™ Platform Versatility and Robustness with Tetanus Toxoid Antigen as a Case Study